Brain, nerves and neurotransmitters
How the nervous system is organized, how one neuron passes a chemical signal to the next, which enzymes make and remove each neurotransmitter, and what decides whether a compound in the blood reaches the brain. Each value is tied to the source it came from.
Azevedo FAC, et al. J Comp Neurol 2009;513:532–541; Kadry H, Noorani B, Cucullo L. Fluids Barriers CNS 2020;17:69; Elmenhorst D, et al. J Nucl Med 2012;53:1723–1729.
Status. Education, not medical advice. EUTECNIQ is in formation and has no laboratory, studies or clinical data. Schematics are drawn for this page and are not to scale; the caffeine occupancy curve is an educational calculation, not a measurement or a prediction for any product.
Related: ADME, PK and PBPK · Blood–brain barrier property rules · Bioactive compounds · Proteins, peptides and collagen
The brain and spinal cord are the central nervous system; every nerve and ganglion outside them is peripheral
The central nervous system (CNS) is the brain and spinal cord. The peripheral nervous system (PNS) is everything else: nerves, which are bundles of axons, and ganglia, which are clusters of nerve-cell bodies. By function, the PNS has a somatic division for conscious perception and voluntary movement, an autonomic division for smooth muscle, heart muscle and glands, and an enteric division in the wall of the gut.
Explanation, details and sources
- Central nervous system. Brain and spinal cord. Regions rich in cell bodies and dendrites are gray matter; regions rich in myelinated axons are white matter. In the CNS a cluster of cell bodies is a nucleus and a bundle of axons is a tract.
- Peripheral nervous system. Structures outside the brain and spinal cord. A cluster of cell bodies is a ganglion and a bundle of axons is a nerve.
- Somatic division. Conscious perception and voluntary motor responses.
- Autonomic division. Involuntary control of smooth muscle, cardiac muscle and glands, mainly for homeostasis. Sympathetic preganglionic neurons sit in the lateral horn of the thoracic and upper lumbar spinal cord; parasympathetic preganglionic neurons sit in brainstem nuclei and the lateral horn of the sacral cord.
- Enteric division. Controls the smooth muscle and glands of the digestive system, is counted as part of the PNS and is not dependent on the brain and spinal cord. Its myenteric plexus, between the longitudinal and circular muscle layers, coordinates movement; its submucosal plexus, nearer the mucosa, regulates secretion.
OpenStax Anatomy and Physiology 2e, §12.1 and §15.1; Walsh KT, Zemper AE. Cell Mol Gastroenterol Hepatol 2019;8:369–378; Tobias A, Sadiq NM. Physiology, Gastrointestinal Nervous Control. StatPearls, updated September 26, 2022.
All ganglionic neurons carry nicotinic receptors; parasympathetic targets carry muscarinic receptors; most sympathetic targets carry α- and β-adrenergic receptors.
Text version of the autonomic chains
- Parasympathetic. Preganglionic neurons in brainstem nuclei (axons in cranial nerves III, VII, IX and X) and the sacral cord release acetylcholine (ACh) onto nicotinic receptors in terminal or intramural ganglia. Postganglionic fibers release ACh onto muscarinic receptors of smooth muscle, cardiac muscle and glands.
- Sympathetic. Preganglionic neurons in the thoracic and upper lumbar cord release ACh onto nicotinic receptors in chain (paravertebral) or collateral (prevertebral) ganglia. Postganglionic fibers release norepinephrine (NE) onto α- and β-adrenergic receptors.
- Sympathetic exception. Postganglionic fibers to sweat glands and to blood vessels of skeletal muscle release ACh.
- Adrenal medulla. Receives sympathetic preganglionic fibers and releases epinephrine and norepinephrine into the bloodstream.
The human brain holds about 86 billion neurons and a similar number of other cells, not ten times more glia
Counts by the isotropic fractionator, which dissolves tissue into a suspension of nuclei and counts neuronal nuclei by their NeuN marker, put the adult male brain at 86.1 ± 8.1 billion neurons and 84.6 ± 9.8 billion non-neuronal cells. The cerebellum holds most of the neurons; the cerebral cortex holds most of the other cells.
Show data: neurons and non-neuronal cells by region
| Region | Neurons, billions | Non-neuronal cells, billions | Source |
|---|---|---|---|
| Whole brain | 86.1 ± 8.1 | 84.6 ± 9.8 | Azevedo et al. 2009, abstract |
| Cerebral cortex, gray and white matter | 16.34 | 60.84 | von Bartheld et al. 2016, Table 1 |
| Cerebellum | 69 | 16 | von Bartheld et al. 2016, Table 4 |
The review that compiled 150 years of counts concluded that histology always supported a glia-to-neuron ratio of about 1:1 for the whole human brain, with 40–130 billion glial cells. The often-repeated figure of one trillion glial cells and a 10:1 ratio is not supported by the original data.
| Cell type | Where | What it does |
|---|---|---|
| Multipolar neuron | CNS and PNS; most neurons | One axon and two or more dendrites |
| Bipolar neuron | Mainly olfactory epithelium and retina | One axon and one dendrite |
| Unipolar (pseudo-unipolar) neuron | Sensory neurons with cell bodies in ganglia | One process that includes both the axon and the dendrite |
| Astrocyte | CNS | Support; maintains extracellular chemical concentrations; contributes to the blood–brain barrier |
| Oligodendrocyte | CNS | Myelinates CNS axons |
| Microglia | CNS | Immune surveillance and phagocytosis |
| Ependymal cell | CNS | Makes cerebrospinal fluid |
| Satellite cell | PNS: sensory and autonomic ganglia | Supports neuron cell bodies |
| Schwann cell | PNS: peripheral nerves | Myelinates one segment of one axon |
OpenStax Anatomy and Physiology 2e, §12.2 (2022); von Bartheld et al. 2016, abstract.
At a chemical synapse an electrical signal becomes a chemical one, and the signal ends when the transmitter is removed
A neuron releases transmitter from vesicles when calcium enters its terminal. The transmitter diffuses across the synaptic cleft and binds receptors on the next cell. Uptake transporters and enzymes then clear it, which sets how long the signal lasts.
Ionotropic receptors are ligand-gated ion channels that mediate fast transmission on a millisecond time scale; metabotropic receptors act through G proteins, effector proteins and second messengers.
Explanation, details and sources
- ArrivalAn action potential reaches the presynaptic terminal and opens voltage-gated Ca²⁺ channels; Ca²⁺ enters.
- LoadingVesicular transporters fill vesicles using the proton gradient made by the vesicular proton ATPase: VGLUT for glutamate, VGAT for GABA and, to a lesser extent, glycine, VAChT for acetylcholine and VMAT2 for dopamine, norepinephrine, epinephrine, serotonin and histamine. VGAT, VAChT and VMAT2 exchange transmitter for protons; VGLUT works mainly as a uniporter driven by the electrical part of the gradient.
- ReleaseCa²⁺ helps the vesicle merge with the membrane; transmitter is released by exocytosis and diffuses across the cleft.
- ReceptorsEach receptor is specific for its transmitter. Ionotropic receptors are ligand-gated ion channels; metabotropic receptors are G protein–coupled and act through effector proteins and second messengers.
- RemovalNa⁺-coupled plasma-membrane transporters take transmitter back into the terminal: DAT (dopamine), NET (norepinephrine), SERT (serotonin), GAT1 (GABA) and GlyT2 (glycine). Amino-acid transmitters are also taken up by nearby glia; EAAT2 carries each glutamate with two or three Na⁺ ions.
- EnzymesAcetylcholinesterase hydrolyzes acetylcholine in the cleft. Monoamine oxidases A and B, on the outer mitochondrial membrane, deaminate monoamines; catechol O-methyltransferase, in soluble and membrane-bound forms, methylates catecholamines. Neuropeptides are cut into inactive fragments by peptidases.
OpenStax Anatomy and Physiology 2e, §12.5 and Table 12.3; Concise Guide to PHARMACOLOGY 2023/24: Ion channels (millisecond time scale); UniProt (accessed October 29, 2026): Q9P2U7, Q9H598, Q16572, Q05940, Q01959, P23975, P31645, P30531, Q9Y345, P43004, P22303, P21397, P27338, P21964; Purves D, et al., eds. Neuroscience, 2nd ed. 2001, “Peptide Neurotransmitters.”
Each neurotransmitter has its own synthesis enzymes, receptor families and route of removal
Small-molecule transmitters are amino acids, amines, purines, lipids and one gas. Neuropeptides are cut from larger precursor proteins. Receptor names below follow the IUPHAR/BPS nomenclature published in the Concise Guide to PHARMACOLOGY.
| Transmitter | Chemical class | Precursor and synthesis | Receptors | Inactivation | Main roles, as sourced |
|---|---|---|---|---|---|
| Glutamate | Amino acid | From glutamine by glutaminase (GLS, EC 3.5.1.2); loaded into vesicles by VGLUT | Ionotropic: AMPA (GluA1–4), kainate (GluK1–5), NMDA (GluN1, GluN2A–D, GluN3A–B). Metabotropic: mGlu1–8 | Uptake by Na⁺-coupled EAATs into neurons and glia; in brain, glutamine synthetase (EC 6.3.1.2) converts it to glutamine | Main excitatory transmitter of the brain; its receptors cause depolarization |
| GABA | Amino acid | From glutamate by glutamate decarboxylase GAD65 or GAD67 (EC 4.1.1.15; cofactor PLP); vesicles via VGAT | GABAA: anion-selective channels assembled from 19 reported subunits. GABAB: GABAB1 + GABAB2 G protein–coupled dimer | Reuptake by GAT1 (Na⁺, Cl⁻); GABA transaminase (EC 2.6.1.19; PLP) | Inhibitory; GABAA receptors mediate fast synaptic and sustained tonic inhibition in the CNS |
| Glycine | Amino acid | Serine and glycine are interconverted by PLP-dependent serine hydroxymethyltransferase (SHMT1, EC 2.1.2.1); VGAT also loads glycine | GlyR anion channels: α1–α3 with β (α4 is a human pseudogene). Also a co-agonist at the GluN1 site of NMDA receptors | GlyT1 and GlyT2 (Na⁺, Cl⁻) | Inhibitory transmission in the spinal cord and brainstem, including motor reflex circuits and synapses onto pain-sensing neurons |
| Acetylcholine | Choline ester | Choline + acetyl-CoA by choline acetyltransferase (ChAT, EC 2.3.1.6); choline enters by CHT1; vesicles via VAChT | Nicotinic pentamers from 16 mammalian subunits (α1–7, α9–10, β1–4, γ, δ, ε); adult muscle type (α1)2β1δε. Muscarinic M1–M5 | Acetylcholinesterase (EC 3.1.1.7) in the cleft | Somatic neuromuscular junction; all autonomic preganglionic fibers; parasympathetic postganglionic fibers |
| Dopamine | Catecholamine | L-tyrosine → L-DOPA by tyrosine hydroxylase (TH, EC 1.14.16.2; BH4, Fe²⁺; rate-limiting) → dopamine by aromatic L-amino acid decarboxylase (AADC, EC 4.1.1.28; PLP); vesicles via VMAT2 | D1, D2, D3, D4, D5 (all G protein–coupled) | DAT; MAO-A and MAO-B (EC 1.4.3.4); COMT (EC 2.1.1.6) | Motivation, reward and reinforcement; coordination of body movements; substantia nigra dopamine neurons degenerate in Parkinson's disease |
| Norepinephrine | Catecholamine | Dopamine → norepinephrine by dopamine β-hydroxylase (DBH, EC 1.14.17.1; Cu, ascorbate, O2) | α1A, α1B, α1D; α2A, α2B, α2C; β1, β2, β3 | NET; MAO-A; COMT | Transmitter of most sympathetic postganglionic fibers; from the locus coeruleus, influences sleep and wakefulness, attention and feeding behavior |
| Epinephrine | Catecholamine | Norepinephrine → epinephrine by phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28; S-adenosylmethionine) | Same adrenoceptors as norepinephrine | MAO; COMT | Hormone of the adrenal medulla, released with norepinephrine into the blood; CNS neurons in two groups in the rostral medulla |
| Serotonin (5-HT) | Indoleamine | L-tryptophan → 5-hydroxytryptophan by tryptophan hydroxylase TPH1 or TPH2 (EC 1.14.16.4; BH4, Fe²⁺; rate-limiting) → serotonin by AADC (PLP) | Ionotropic 5-HT3. G protein–coupled: 5-HT1A, 1B, 1D, 1e, 1F, 5-HT2A, 2B, 2C, 5-HT4, 5-HT5A, 5-HT6, 5-HT7 | SERT; MAO-A, which preferentially oxidizes serotonin | Made by neurons of the raphe region of the pons and upper brainstem; implicated in sleep and wakefulness. Precursor of melatonin in the pineal gland |
| Histamine | Imidazole amine | L-histidine → histamine by histidine decarboxylase (HDC, EC 4.1.1.22; PLP) | H1, H2, H3, H4 | Histamine N-methyltransferase (HNMT, EC 2.1.1.8; S-adenosylmethionine); methylhistamine is a MAO-B substrate | Made by hypothalamic neurons; central histamine projections mediate arousal and attention; mast-cell histamine acts in allergic reactions |
| Adenosine and ATP | Purines | Extracellular ATP → AMP by ectonucleoside triphosphate diphosphohydrolase 1 (CD39, EC 3.6.1.5) → adenosine by ecto-5′-nucleotidase (CD73, EC 3.1.3.5) | Adenosine: A1, A2A, A2B, A3. ATP: ionotropic P2X1–7; G protein–coupled P2Y1, 2, 4, 6, 11, 12, 13, 14 | Adenosine: ENT1 transport; adenosine deaminase (EC 3.5.4.4); adenosine kinase (EC 2.7.1.20) | Adenosine is a neuromodulator; caffeine's stimulating effects at common doses come from blocking adenosine receptors |
| Anandamide | Lipid: N-acylethanolamine | From membrane N-acyl-phosphatidylethanolamines; NAPE-PLD (EC 3.1.4.54) is one route, mainly yielding saturated and monounsaturated acylethanolamines in brain | CB1, CB2; some cannabinoids also engage TRP channels and PPARs | Fatty acid amide hydrolase (FAAH, EC 3.5.1.99) | Endocannabinoid system: CNS development, synaptic plasticity and responses to insults |
| 2-Arachidonoylglycerol (2-AG) | Lipid: monoacylglycerol | From arachidonoyl-containing diacylglycerol by diacylglycerol lipase α (DAGLα, EC 3.1.1.116; Ca²⁺) | CB1, CB2 | Monoacylglycerol lipase (MAGL, EC 3.1.1.23); FAAH also hydrolyzes it | Retrograde suppression at central synapses |
| Nitric oxide | Gas | L-arginine → NO + L-citrulline by neuronal NO synthase (nNOS, EC 1.14.13.39; NADPH, O2, BH4, FAD, FMN, heme), activated by Ca²⁺/calmodulin | NO-sensitive (soluble) guanylyl cyclase, which makes cGMP | Consumed rapidly as it diffuses through tissue (shown in brain slices) | Formed after NMDA receptor activation; changes neuronal excitability and synaptic strength, acting pre- or postsynaptically |
| Substance P | Peptide, 11 amino acids | Cut from the TAC1 precursor | NK1 (substance P most potent), NK2, NK3 | Peptidases | Sensory transmitter in the spinal cord; involved in the perception of pain; present at high concentrations in parts of the brain and in the gut |
| Opioid peptides | Peptides: endorphins, enkephalins (Met-enkephalin, 5 amino acids), dynorphins (dynorphin A, 17) | Three precursor genes: proopiomelanocortin (POMC), proenkephalin (PENK), prodynorphin (PDYN) | μ, δ, κ; nociceptin acts at NOP | Peptidases | Perception of pain; in general they tend to be depressants |
| Orexin-A, orexin-B | Peptides, 33 and 28 amino acids | Both cut from prepro-orexin (HCRT) | OX1, OX2 | Peptidases | Made by neurons in and around the lateral and posterior hypothalamus (rat); stimulate feeding when given into rat brain (animal finding). All six human narcolepsy brains examined in one study showed a global loss of these peptides (hypocretins) |
| Oxytocin | Peptide, 9 amino acids | Made by paraventricular hypothalamic neurons; stored in posterior pituitary terminals | OT receptor | Peptidases | Uterine contraction and cervical dilation; milk ejection reflex |
| Vasopressin (antidiuretic hormone) | Peptide, 9 amino acids | Made by supraoptic hypothalamic neurons; stored in posterior pituitary terminals | V1A, V1B, V2 | Peptidases | Raises renal water reabsorption; constricts blood vessels at very high concentrations |
| Neuropeptide Y | Peptide, 36 amino acids | Cut from the NPY precursor | Y1, Y2, Y4, Y5 | Peptidases | Centrally promotes feeding and reduces energy expenditure |
Sources for the table, row by row
Enzymes, EC numbers, cofactors, reactions and transporter functions: UniProtKB/Swiss-Prot human entries, accessed October 29, 2026: GLS O94925, GLUL P15104, GAD1 Q99259, GAD2 Q05329, ABAT P80404, SHMT1 P34896, CHAT P28329, ACHE P22303, TH P07101, DDC P20711, DBH P09172, PNMT P11086, TPH1 P17752, TPH2 Q8IWU9, AANAT Q16613, ASMT P46597, HDC P19113, HNMT P50135, MAOA P21397, MAOB P27338, COMT P21964, ENTPD1 P49961, NT5E P21589, ADA P00813, ADK P55263, SLC29A1 Q99808, NAPEPLD Q6IQ20, FAAH O00519, DAGLA Q9Y4D2, MGLL Q99685, NOS1 P29475, SLC17A7 Q9P2U7, SLC32A1 Q9H598, SLC18A3 Q16572, SLC5A7 Q9GZV3, SLC18A2 Q05940, SLC6A1–SLC6A5 and SLC6A9, SLC1A2 P43004. Peptide lengths: UniProt peptide features of TAC1 P20366, PENK P01210, PDYN P01213, HCRT O43612, OXT P01178, AVP P01185, NPY P01303.
Receptors: Concise Guide to PHARMACOLOGY 2025/26 (G protein-coupled receptors) and 2023/24 (Ion channels), Br J Pharmacol.
Roles: glutamate, GABA and glycine as excitatory or inhibitory: OpenStax §12.5 and UniProt GLS; GABAA: Concise Guide 2023/24; glycine: Lynch JW. Physiol Rev 2004;84:1051–1095; acetylcholine: OpenStax §15.1 and Concise Guide (muscle type); dopamine, norepinephrine, epinephrine, serotonin, histamine: Purves et al., Neuroscience 2nd ed. 2001, “The Biogenic Amines”; MAO substrates: StatPearls, Monoamine Oxidase Inhibitors (MAOIs), updated December 13, 2025; adenosine: Elmenhorst et al. 2012; endocannabinoids: Lu H-C, Mackie K. Biol Psychiatry 2016;79:516–525 and UniProt DAGLA; nitric oxide: Garthwaite 2008; substance P and opioid peptides: Purves et al., “Peptide Neurotransmitters”; orexins: Sakurai T, et al. Cell 1998;92:573–585 and Peyron C, et al. Nat Med 2000;6:991–997; oxytocin and vasopressin: OpenStax §17.3; neuropeptide Y: Tatemoto K. PNAS 1982;79:5485–5489 and Loh K, Herzog H, Shi Y-C. Trends Endocrinol Metab 2015;26:125–135.
Most small-molecule transmitters are one to four enzyme steps from an amino acid, and several steps need vitamin-derived cofactors
Tyrosine, tryptophan, histidine, glutamine and arginine are amino acids; choline is a nutrient. The decarboxylases and transaminases need pyridoxal 5′-phosphate (PLP), an active coenzyme form of vitamin B6. The two rate-limiting hydroxylases use tetrahydrobiopterin (BH4) and iron, and the methyltransferases use S-adenosylmethionine (SAM).
Text version of the pathways
- Catecholamines. L-tyrosine + BH4 + O2 → L-DOPA (tyrosine hydroxylase, Fe²⁺); L-DOPA → dopamine + CO2 (AADC, PLP); dopamine + 2 ascorbate + O2 → norepinephrine (DBH, Cu); norepinephrine + SAM → epinephrine (PNMT).
- Serotonin and melatonin. L-tryptophan + BH4 + O2 → 5-hydroxytryptophan (TPH1 or TPH2, Fe²⁺); → serotonin + CO2 (AADC, PLP); serotonin + acetyl-CoA → N-acetylserotonin (AANAT, which sets the night–day rhythm of melatonin production in the pineal gland); N-acetylserotonin + SAM → melatonin (ASMT).
- GABA. L-glutamine → L-glutamate (glutaminase); L-glutamate → GABA + CO2 (GAD65 or GAD67, PLP); GABA → succinic semialdehyde (GABA transaminase, PLP).
- Acetylcholine. Choline + acetyl-CoA → acetylcholine + CoA (ChAT); acetylcholine + H2O → choline + acetate (AChE); the high-affinity transporter CHT1 brings choline into the terminal.
- Histamine. L-histidine → histamine + CO2 (HDC, PLP); histamine + SAM → Nτ-methylhistamine (HNMT).
- Nitric oxide. 2 L-arginine + 3 NADPH + 4 O2 → 2 L-citrulline + 2 NO (nNOS; heme, FAD, FMN and BH4 as cofactors).
Related Supplements A–Z entries: Vitamin B6, Choline, Melatonin, Vitamin C, Copper, Iron. Those pages cover the nutrients themselves; this page states only the enzyme chemistry.
Human studies and FDA labeling document specific links between diet and these pathways
The interactions below were measured in people or are stated in FDA-approved labeling. Mechanisms seen only in cells or animals are labeled as laboratory findings. None of this is advice to take or avoid a product.
Show data: calculated A1 receptor occupancy
| Plasma caffeine, µmol/L | mg/L | Calculated occupancy | Range |
|---|---|---|---|
| 10 | 1.9 | 13% | Measured range |
| 25 | 4.9 | 27% | Measured range |
| 46.3 | 9.0 | 41% | Upper end of measured range |
| 67 | 13.0 | 50% | Extrapolated |
| 100 | 19.4 | 60% | Extrapolated |
| 150 | 29.1 | 69% | Extrapolated |
| Interaction | What was found | Evidence |
|---|---|---|
| Caffeine and adenosine receptors (Caffeine) | Caffeine is a nonselective adenosine receptor antagonist. In 15 healthy men, PET with 18F-CPFPX showed caffeine displacing 5–44% of A1 receptor binding, with half-maximal displacement at 67 µM plasma caffeine, which the authors equate to about 450 mg in a 70-kg adult or about 4.5 cups of coffee. They estimate that repeated beverages over a day might occupy up to 50% of brain A1 receptors. | Human PET study |
| Protein or carbohydrate meals and the tryptophan ratio | The large neutral amino acids share one competitive transporter at the blood–brain barrier. In 8 adults who ate both test breakfasts, the plasma tryptophan to large-neutral-amino-acid ratio differed by a median 54% (range 36–88%) between a carbohydrate-rich and a protein-rich breakfast, and the tyrosine ratio by 28% (10–64%). Brain uptake itself was not measured; the authors wrote that brain tryptophan “probably” follows. | Human plasma data |
| Vitamin B6 and levodopa (Vitamin B6) | FDA-approved labeling for carbidopa–levodopa states that pyridoxine hydrochloride in oral doses of 10–25 mg may reverse the effects of levodopa given alone by increasing the rate of aromatic amino acid decarboxylation, and that carbidopa inhibits this action. | FDA-approved label |
| Dietary protein and levodopa absorption | The same label states that levodopa competes with certain amino acids for transport across the gut wall, so its absorption may be impaired in some patients on a high-protein diet. | FDA-approved label |
| Tyramine and monoamine oxidase inhibitors | MAO inhibitors prevent the breakdown of tyramine from food, drinks and some medicines; high tyramine can cause a sudden rise in blood pressure, the tyramine pressor response. Dopamine and tyramine are metabolized by both MAO-A and MAO-B. | Clinical review (StatPearls) |
| L-DOPA and the LAT1 transporter | L-DOPA uptake by a mouse brain capillary endothelial cell line had the characteristics of 4F2hc/LAT1, and immunostaining found LAT1 mainly in CNS microvessels. | Laboratory finding (cell line, tissue staining) |
Elmenhorst et al. 2012; Fernstrom JD. Amino Acids 2013;45:419–430; Wurtman RJ, et al. Am J Clin Nutr 2003;77:128–132; SINEMET (carbidopa and levodopa) tablets, prescribing information, Organon LLC, DailyMed set ID 9b17b028-964a-473c-823d-81423535bd66 (published August 24, 2026); Patel P, Saadabadi A. Monoamine Oxidase Inhibitors (MAOIs). StatPearls, updated December 13, 2025; Kageyama T, et al. Brain Res 2000;879:115–121. Related entry: Melatonin (made from serotonin in the pineal gland).
Brain capillaries are sealed by tight junctions, lined with efflux pumps and wrapped by pericytes and astrocyte endfeet
Brain capillary endothelial cells differ from those elsewhere in three ways: tight junctions close the gaps between them, they have no fenestrations, and they lack pinocytic activity. Pericytes share their basement membrane, and astrocyte endfeet cover close to 99% of the outer capillary surface. The physicochemical rules of thumb for passive entry are on the ADME, PK and PBPK page.
Claudins bind claudins on the neighboring cell to form the primary seal; in brain endothelium claudin-1 and claudin-5 with occludin are the main tight-junction proteins.
Explanation, details and sources
- Tight junctions. Built from three integral membrane proteins, claudins, occludin and junctional adhesion molecules (JAMs), and cytoplasmic proteins including ZO-1, ZO-2 and ZO-3 that link them to actin. Mice genetically lacking claudin-5 had a severely leaky blood–brain barrier and died shortly after birth (animal finding); occludin-deficient mice were viable with intact barriers.
- Endothelial cells. No fenestrations, a lack of pinocytic activity, and ATP-driven efflux pumps on the blood-facing (luminal) membrane. The luminal and abluminal membranes are about 500 nm apart or less.
- Pericytes. Most abundant in the CNS; they share the basement membrane with endothelial cells and make peg-and-socket contacts with them through N-cadherin and connexins.
- Astrocytes. Their foot processes cover close to 99% of the abluminal capillary surface and form the interface between the vessel and the neural tissue.
- Estimate of the barrier's reach. Pardridge estimated that the blood–brain barrier excludes about 100% of large-molecule drugs and more than 98% of small-molecule drugs from the brain.
Kadry et al. 2020; UniProt O00501 (claudin-5: tight junction-specific obliteration of the intercellular space), Q07157 (ZO-1); Pardridge WM. NeuroRx 2005;2:3–14.
Small lipophilic molecules diffuse in; nutrients need carriers, large proteins need receptors, and efflux pumps send many drugs back
Lipid-soluble molecules under about 400 Da that form fewer than 8 hydrogen bonds can cross the endothelium by free diffusion. Glucose, amino acids and other nutrients use solute carriers, and larger molecules such as insulin, leptin and iron-loaded transferrin are taken up by receptor-mediated endocytosis.
Text version of the routes
- ParacellularTight junctions prevent unregulated passage of polar, water-soluble molecules between endothelial cells.
- Passive transcellular diffusionSmall lipid-soluble molecules, molecular weight below 400 Da and fewer than 8 hydrogen bonds. Above 400 Da, permeability no longer rises in proportion to lipid solubility.
- Carrier-mediated transportGLUT1 carries glucose and is the brain's most important energy carrier at the barrier; LAT1 (with 4F2hc) exchanges large neutral amino acids and carries L-DOPA; MCT1 carries lactate, pyruvate and ketone bodies; ENT1 and the concentrative nucleoside transporters carry nucleosides such as adenosine.
- Receptor-mediated transcytosisA ligand binds its receptor, is taken into a vesicle and released on the brain side: transferrin by the transferrin receptor, insulin by the insulin receptor.
- Adsorptive-mediated transcytosisPositively charged large molecules bind cell-surface sites that trigger endocytosis and transcytosis.
- Active effluxP-gp (ABCB1) and BCRP (ABCG2) sit on the luminal membrane and pump substrates from the endothelium back into blood, with overlapping substrates; MRPs (ABCC family) appear on either the luminal or the abluminal membrane and favor water-soluble conjugates as substrates.
Circumventricular organs are midline structures around the third and fourth ventricles; most of them lack a blood–brain barrier (the subcommissural organ is usually described as the exception). They are sites of communication with the cerebrospinal fluid and, through blood-borne products, between the brain and peripheral organs.
| Circumventricular organ | Type | Neurons present |
|---|---|---|
| Subfornical organ | Sensory | Yes |
| Area postrema | Sensory | Yes |
| Organum vasculosum of the lamina terminalis | Sensory | Yes |
| Pineal gland | Secretory | No |
| Median eminence | Secretory | No |
| Neurohypophysis (posterior pituitary) | Secretory | No |
| Subcommissural organ | Secretory | Yes |
Kaur C, Ling EA. Histol Histopathol 2017;32:879–892 (abstract).
Brain penetration is measured as an unbound concentration ratio or, in people, as receptor occupancy by PET
A total brain-to-blood ratio mixes barrier transport with binding to brain tissue and plasma proteins. The unbound ratio Kp,uu isolates what the barrier does, and positron emission tomography (PET) shows how much of a target a compound occupies in a living human brain.
Unbound ratio at steady stateKp,uu = Cu,brain ISF / Cu,plasma
Show data: Kp,uu in rats
| Drug | Kp,uu as printed | Original study |
|---|---|---|
| Oxycodone | 3.03 (0.038) | Boström et al. 2006 |
| YM992 | 1.42 ± 0.81 | Mano et al. 2002 |
| Codeine | 1.06 ± 0.12 | Xie and Hammarlund-Udenaes 1998 |
| Morphine | 0.51 ± 0.18 | Stain-Texier et al. 1999 |
| Morphine | 0.29 ± 0.07 | Tunblad et al. 2003 |
| M6G | 0.56 ± 0.18 | Stain-Texier et al. 1999 |
| M6G | 0.29 | Tunblad et al. 2005 |
| M6G | 0.22 ± 0.09 | Bouw et al. 2001 |
| Gabapentin | 0.12 | Wang and Welty 1996 |
| M3G | 0.08 ± 0.02 | Xie et al. 2000 |
| Baclofen | 0.022 | Deguchi et al. 1995 |
Among CNS-active drugs Kp,uu differs by up to 150-fold, total Kp (logBB) by at least 2,000-fold and barrier permeability by at least 20,000-fold.
Show data: brain H1 receptor occupancy by antihistamine
| Drug and dose | Occupancy | Spread reported | Study |
|---|---|---|---|
| (+)-Chlorpheniramine 5 mg intravenous | 98.2% | ± 1.2 | Yanai 1995 |
| (+)-Chlorpheniramine 2 mg oral | 76.8% | ± 4.2 | Yanai 1995 |
| Diphenhydramine 30 mg | 56.4% | mean of 8 men | Tashiro 2008 |
| d-Chlorpheniramine 2 mg | 53.0% | ± 33.2 | Kubo 2011 |
| Cetirizine 20 mg | 26.0% | mean | Tashiro 2004 |
| Terfenadine 60 mg | 17.2% | ± 14.2 | Yanai 1995 |
| Bepotastine 10 mg | 14.7% | mean of 8 men | Tashiro 2008 |
| Loratadine 10 mg | 11.7% | ± 19.5 | Kubo 2011 |
| Ebastine 10 mg | about 10% | approximate | Tagawa 2001 |
| Levocetirizine 5 mg | 8.1% | 95% CI −9.8 to 26.0 | Hiraoka 2015 |
| Fexofenadine 120 mg | −0.1% | mean | Tashiro 2004 |
| Fexofenadine 60 mg | −8.0% | 95% CI −26.7 to 10.6 | Hiraoka 2015 |
| Compound | Reaches the brain? | What shows it |
|---|---|---|
| Loperamide | Not at usual doses; yes when P-gp is inhibited | In 8 healthy men, 16 mg loperamide alone caused no respiratory depression; with 600 mg quinidine, a P-gp inhibitor, it did (P <.001), and plasma loperamide did not explain the change. That loperamide is a P-gp substrate came from in vitro studies. |
| Dopamine, levodopa, carbidopa | Dopamine no; levodopa yes; carbidopa no | FDA-approved labeling: dopamine does not cross the blood–brain barrier, its precursor levodopa does, and carbidopa, which blocks peripheral decarboxylation of levodopa, does not cross and does not affect levodopa metabolism in the brain. |
| Antihistamines | Diphenhydramine and chlorpheniramine occupied about half or more of brain H1 receptors; fexofenadine's occupancy was negligible | Human PET occupancy of brain H1 receptors (figure above). |
| Caffeine | Yes | Concentration-dependent displacement of an A1 receptor PET tracer after intravenous caffeine in 15 healthy men. |
Sadeque AJM, et al. Clin Pharmacol Ther 2000;68:231–237; SINEMET prescribing information (DailyMed, 2026); Elmenhorst et al. 2012. Related: CNS MPO score and property rules; pharmacokinetic equations.
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.